Thyroid Hormone Excess Rather Than Thyrotropin Deficiency Induces Osteoporosis in Hyperthyroidism

Thyrotoxicosis is an important but under recognized cause of osteoporosis. Recently, TSH deficiency, rather than thyroid hormone excess, has been suggested as the underlying cause. To investigate the molecular mechanism of osteoporosis in thyroid disease, we characterized the skeleton in mice lackin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular endocrinology (Baltimore, Md.) Md.), 2007-05, Vol.21 (5), p.1095-1107
Hauptverfasser: Bassett, J. H. Duncan, O’Shea, Patrick J, Sriskantharajah, Srividya, Rabier, Bénédicte, Boyde, Alan, Howell, Peter G. T, Weiss, Roy E, Roux, Jean-Paul, Malaval, Luc, Clement-Lacroix, Phillipe, Samarut, Jacques, Chassande, Olivier, Williams, Graham R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Thyrotoxicosis is an important but under recognized cause of osteoporosis. Recently, TSH deficiency, rather than thyroid hormone excess, has been suggested as the underlying cause. To investigate the molecular mechanism of osteoporosis in thyroid disease, we characterized the skeleton in mice lacking either thyroid hormone receptor α or β (TRα0/0, TRβ−/−). Remarkably, in the presence of normal circulating thyroid hormone and TSH concentrations, adult TRα0/0 mice had osteosclerosis accompanied by reduced osteoclastic bone resorption, whereas juveniles had delayed endochondral ossification with reduced bone mineral deposition. By contrast, adult TRβ−/− mice with elevated TSH and thyroid hormone levels were osteoporotic with evidence of increased bone resorption, whereas juveniles had advanced ossification with increased bone mineral deposition. Analysis of T3 target gene expression revealed skeletal hypothyroidism in TRα0/0 mice, but skeletal thyrotoxicosis in TRβ−/− mice. These studies demonstrate that bone loss in thyrotoxicosis is independent of circulating TSH levels and mediated predominantly by TRα, thus identifying TRα as a novel drug target in the prevention and treatment of osteoporosis.
ISSN:0888-8809
1944-9917
DOI:10.1210/me.2007-0033